CCDS 09/2010 Page 1 of 19
|
|
- Tobias Franklin
- 5 years ago
- Views:
Transcription
1 PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) SPORANOX 10 mg/ml Oral solution. COMPOSITION Each millilitre oral solution contains 10 mg of itraconazole. Sporanox Oral solution contains itraconazole as the active ingredient. Inactive ingredients include the following: Hydroxypropyl-β-cyclodextrin, sorbitol, propylene glycol, hydrochloric acid, cherry flavor 1, cherry flavor 2, caramel, sodium saccharin, sodium hydroxide, purified water. PHARMACOLOGICAL CLASSIFICATION A Antimicrobial (chemotherapeutic) agents. Fungicides. PHARMACOLOGICAL ACTION Pharmacodynamic properties Itraconazole is a triazole derivative. In vitro studies demonstrate that itraconazole inhibits the growth of the following fungi pathogenic for humans, at concentrations usually ranging from 0,025 0,8 g/ml: dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton floccosum); yeasts (Cryptococcus neoformans, Candida spp.); Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis; Sporothrix schenkii; Blastomyces dermatitidis; Pseudallescheria boydii, Penicillium marneffei. Page 1 of 19
2 Candida Krusei, Candida glabrata and Candida tropicalis are the least susceptible Candida species, with isolates showing unequivocal resistance to itraconazole in vitro. The principal fungus types that are not inhibited by itraconazole are Zygomycetes (e.g. Rhizopus spp., Rhizomucor spp., Mucor spp. and Absidia spp.), Fusarium spp., Scedosporium spp. and Scopulariopsis spp. In vitro studies have demonstrated that itraconazole impairs the synthesis of ergosterol in fungal cells. Ergosterol is a vital cell membrane component in fungi. Impairment of its synthesis ultimately results in an antifungal effect. In vitro activity does not necessarily imply clinical efficacy. Pharmacokinetic properties General pharmacokinetic characteristics Peak plasma concentrations are reached within 2,5 hours following administration of the oral solution. Itraconazole undergoes extensive hepatic metabolism to give numerous metabolites. The main metabolite is hydroxy-itraconazole, with plasma concentrations about twice those of the unchanged medicine. The terminal half-life of itraconazole is about 40 hours after repeated dosing. The pharmacokinetics of itraconazole is characterized by non-linearity and, consequently, shows accumulation in plasma after multiple dose administration. Steady state concentrations are reached within 15 days, with C max values of about 2 μg/ml after oral administration of 200 mg once daily. Itraconazole clearance decreases at higher doses due to a saturable mechanism of its hepatic metabolism. Itraconazole is excreted as inactive metabolites in the urine (~ 35 %) and in faeces (~ 54 %). Page 2 of 19
3 Absorption The observed absolute bioavailability of itraconazole under fed conditions is about 55 % and is increased by 30 % when the oral solution is taken in fasting conditions. Distribution Most of the itraconazole in plasma is bound to protein (99,8 %) with albumin being the main binding component (99,6 % for the hydroxy-metabolite). It has also a marked affinity for lipids. Only 0,2 % of the itraconazole in plasma is present as free medicine. Itraconazole is distributed in a large apparent volume in the body (> 700 L): concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than the corresponding concentrations in plasma. Brain to plasma ratios were about 1. The uptake into keratinous tissues, skin in particular, is up to four times higher than in plasma. Metabolism Itraconazole is extensively metabolised by the liver into a large number of metabolites. The main metabolite is hydroxy-itraconazole, which has in vitro antifungal activity comparable to itraconazole. Plasma concentrations of the hydroxy-metabolite are about twice those of itraconazole. As shown in in-vitro studies, CYP3A4 is the major enzyme that is involved in the metabolism of itraconazole. Excretion Itraconazole is excreted as inactive metabolites to about 35 % in urine within one week and to about 54 % with faeces. Renal excretion of the parent drug accounts for less than 0,03 % of the dose, whereas faecal excretion of unchanged drug varies between 3 18% of the dose. Page 3 of 19
4 SPECIAL POPULATIONS Hepatic impairment Itraconazole is predominantly metabolised in the liver. A single oral dose (100 mg capsule) was administered to 12 patients with cirrhosis and six healthy control subjects: C max, AUC and terminal half-life of itraconazole were measured, and compared between groups. itraconazole C max was reduced significantly (by 47 %) in patients with cirrhosis. Mean Mean elimination half-life was prolonged significantly compared to that found in subjects without hepatic impairment (37 vs. 16 hours, respectively). Overall exposure to intraconazole, based on AUC was significantly increased in cirrhotic patients and in healthy subjects. Data are not available on efficacy and safety in cirrhotic patients during long-term use of itraconazole (See section on DOSAGE AND DIRECTIONS FOR USE and Special Precautions). Renal impairment Limited data are available on the use of oral itraconazole in patients with renal impairment. Caution should be exercised when the medicine is administered in this patient population. The elimination t 1/2 was increased from 18 to 24 hours. There are no safety data of repeated dosages under renal impairment. INDICATIONS SPORANOX 10 mg/ml Oral solution is indicated: - For the treatment of oral and/or oesophageal candidiasis in HIV seropositive or AIDS or other immunocompromised patients. - As prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole when standard therapy is considered inappropriate in patients with haematological malignancy or undergoing bone marrow transplant and who are expected to become neutropenic (i.e. Page 4 of 19
5 < 500 cells/ l). At present there are insufficient clinical efficacy data in the prevention of aspergillosis. CONTRA-INDICATIONS SPORANOX 10 mg/ml Oral solution is contra-indicated in pregnant women. Women of childbearing potential using SPORANOX 10 mg/ml oral solution should take adequate contraceptive precautions until the next menstrual period following the end of SPORANOX therapy. (See PREGNANCY and LACTATION). Co-administration of the following medicine is contra-indicated with SPORANOX oral solution: (See also WARNINGS and INTERACTIONS). CYP3A4 metabolised substrates can prolong the QT interval, e.g. bepridil, mizolastine, cisapride, dofetilide, quinidine, pimozide, levacetylmethadol, sertindole are contra-indicated with SPORANOX oral solution. CYP3A4 metabolised HMG-CoA reductase inhibitors such as simvastatin and lovastatin. Triazolam and oral midazolam. Ergotalkaloids such as dihydroergotamine, ergometrine, ergotamine and methylergometrine. Nisoldipine, nifedipine and felodipine. SPORANOX Oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF except for the treatment of life-threatening or other serious infections. (See WARNINGS and Special Precautions for use). Page 5 of 19
6 SPORANOX Oral solution must not be used during pregnancy. (See section on PREGNANCY and LACTATION). SPORANOX 10 mg/ml Oral solution is contra-indicated in patients with a known hypersensitivity to the medicine or its excipients. SPORANOX has been shown to have no benefit in the prophylaxis of cryptococcal meningitis in HIV infected patients. WARNINGS Hepatic effects: Cases of serious, usually reversible idiosyncratic hepatitis, which may be fatal, have been observed. Serious hepatotoxicity, including cases of fatal acute liver failure, has occurred with the use of SPORANOX. Most of these cases involved patients, who had pre-existing liver disease, were treated for systemic indications, had significant other medical conditions and/or were taking other hepatotoxic medicines. Some patients had no obvious risk factors for liver disease. These cases have been observed within the first week of treatment up to 1½ years after continuous use of SPORANOX. Liver function should be monitored in patients receiving SPORANOX treatment. Patients should be instructed to promptly report to their medical practitioner signs and symptoms suggestive of hepatitis such as anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine. In these patients treatment should be stopped immediately and liver function Page 6 of 19
7 testing should be conducted. In patients with raised liver enzymes or active disease, or who have experienced liver toxicity with other medicines, treatment should not be started unless the expected benefit exceeds the risk of hepatic injury. In such cases liver enzyme monitoring is necessary. Treatment of severely neutropenic patients SPORANOX Oral solution as treatment for oral and/or oesophageal candidiasis was not investigated in severely neutropenic patients. Due to the pharmacokinetic properties, SPORANOX Oral solution is not recommended for initiation of treatment in patients at immediate risk of systemic candidiasis. Neuropathy If neuropathy occurs that may be attributable to SPORANOX 10 mg/ml Oral solution, the treatment should be discontinued. Renal impairment Limited data are available on the use of oral itraconazole in patients with renal impairment. Caution should be exercised when SPORANOX is administered in this patient population (See Pharmacokinetic properties, Special Populations). The elimination half-life was increased from 18 to 24 hours. There are no safety data of repeated dosages under renal impairment. Hearing Loss Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. The hearing loss may resolve when treatment is stopped, but can persist in some patients. Page 7 of 19
8 INTERACTIONS SPORANOX Oral solution has a potential for clinically important medicine interactions see below. 1. Medicines affecting the metabolism of SPORANOX Oral solution: Enzyme-inducing medicines such as rifampicin, rifabutin, carbamazepine, isoniazid and phenytoin significantly reduce the bioavailability of itraconazole. Monitoring of plasma concentrations of SPORANOX Oral solution is advised if these medicines are administered concomitantly. An increase in the dose of SPORANOX Oral solution may be necessary. As itraconazole is mainly metabolised through CYP3A4, potent inhibitors of this enzyme may increase the bioavailability of SPORANOX Oral solution. Examples are: ritonavir, indinavir, clarithromycin and erythromycin. 2. Effect of SPORANOX Oral solution on the metabolism of other medicines: 2.1 SPORANOX Oral solution can inhibit the metabolism of agents metabolised by the cytochrome 3A family. This can result in an increase and/or prolongation of their effects, including side-effects. When using concomitant medication, the corresponding label should be consulted for information on the route of metabolism. After stopping treatment, itraconazole plasma levels decline gradually, depending on the dose and duration of treatment. (See Pharmacokinetic properties). This should be taken into account when the inhibitory effect of SPORANOX Oral solution on co-medicated medicines is considered. Examples are: Medicines that should not be used during treatment with SPORANOX Oral solution: Page 8 of 19
9 Bepridil, mizolastine, cisapride, dofetilide, quinidine, pimozide, levacetylmethadol and sertindole, since co-administration may result in increased plasma concentrations of these substrates, which can lead to QT prolongation and rare occurrences of Torsade de Pointes. Triazolam and oral midazolam. CYP3A4 metabolised HMG-CoA reductase inhibitors such as simvastatin and lovastatin. (See Contra-indications.) Ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine and methylergometrine. Nisoldipine Calcium channel blockers can have negative inotropic effects which may be additive to those of SPORANOX Oral solution; SPORANOX Oral solution can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when coadministering SPORANOX Oral solution and calcium channel blockers due to an increased risk of CHF. Medicines, whose plasma concentrations, effects or side effects should be monitored. Their dosage, if co-administered with SPORANOX Oral solution, should be reduced if necessary Oral anticoagulants; Prothrombin time should be carefully monitored. HIV Protease Inhibitors such as ritonavir, indinavir, saquinavir. Page 9 of 19
10 Certain antineoplastic agents such as vinca alkaloids, busulphan, docetaxel and trimetrexate. CYP3A4 metabolised calcium channel blockers such as dihydropyridine (e.g. nifedipine, felodipine, nisoldipine) and verapamil. Patients should be monitored for side effects, e.g. oedema. Certain immunosuppressive agents: cyclosporine, tacrolimus, rapamycin (also known as sirolimus). Certain CYP3A4 metabolised HMG-CoA reductase inhibitors such as atorvastatin. Certain glucocorticosteroids such as budesonide, dexamethasone, fluticasone and methyl prednisolone. Others: digoxin (via inhibition of P-glycoprotein), carbamazepine, buspirone, alfentanil, alprazolam, brotizolam, midazolam IV, rifabutin, ebastine, reboxetine, cilostazol, disopyramide, eletriptan, fentanyl, halofantrine and repaglinide. Severe hypoglycaemia has been reported in patients concomitantly receiving azole antifungal agents such as SPORANOX Oral solution and oral hypoglycaemic agents such as tolbutamide, chlorpropamide, glyburide and glipizide. Blood glucose concentrations should be carefully monitored when SPORANOX Oral solution and oral hypoglycaemic agents are coadministered. 2.2 No interaction of SPORANOX Oral Solution with zidovudine (AZT) and fluvastatin has been observed. No inducing effects of SPORANOX Oral Solution on the metabolism of ethinyloestradiol and norethisterone were observed. Page 10 of 19
11 3. Effect on protein binding: Despite the fact that SPORANOX Oral solution is 99,8 % bound to plasma proteins, in vitro studies have shown that there are no interactions on the plasma protein binding between itraconazole and imipramine, propranolol, diazepam, cimetidine, indomethacin, and sulfamethazine. PREGNANCY AND LACTATION Pregnancy SPORANOX Oral solution must not be used during pregnancy. (See CONTRA- INDICATIONS). In animal studies itraconazole has shown to cause congenital abnormalities. During post-marketing experience, cases of congenital abnormalities have been reported. These cases include skeletal, genitourinary tract, cardiovascular and ophthalmic malformations as well as chromosomal and multiple malformations. Women of childbearing potential Women of childbearing potential taking SPORANOX Oral solution should use contraceptive precautions. Effective contraception should be continued until the menstrual period following the end of SPORANOX Oral solution therapy. Lactation Itraconazole is excreted in human milk. The patient should not breast-feed. Page 11 of 19
12 DOSAGE AND DIRECTIONS FOR USE Treatment of oral and/or oesophageal candidiasis: 200 mg (2 x 10 ml measuring cups) per day in one or two intakes for 1 week. If there is no response after 1 week, treatment should be continued for another week. Prophylaxis of fungal infections: 5 mg/kg per day administered in two intakes. In clinical trials, prophylaxis treatment was started immediately prior to the cytostatic treatment and generally one week before transplant procedure. Treatment was continued until recovery of neutrophils (i.e. > cells/ l). Use in children: Since clinical data on the use of SPORANOX Oral solution in paediatric patients is limited, its use in children is not recommended. Use in elderly: As for paediatric use. Use in patients with hepatic impairment: Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Use in patients with renal impairment: Limited data are available on the use of oral itraconazole in patients with renal impairment SIDE EFFECTS AND SPECIAL PRECAUTIONS Clinical trials The table below shows the adverse events reported among patients in clinical trials (pooled data) of SPORANOX Oral solution in the treatment of oropharyngeal and oesophageal Page 12 of 19
13 candidiosis. It includes all adverse events (with an incidence of 2 % or greater) reported among SPORANOX Oral solution -treated patients. About 44 % of patients treated with SPORANOX Oral solution experienced at least one adverse event. Page 13 of 19
14 Table 1: Adverse events reported among SPORANOX Oral solution -treated patients with an incidence of 2 %. SPORANOX Oral solution N= 543 % Body as a whole general disorders Fever Death Gastrointestinal disorders Diarrhoea Nausea Vomiting Abdominal pain Central and peripheral nervous system disorders Headache Respiratory system disorders Coughing Skin and appendages disorders Rash Special senses, other disorders Taste perversion 10,3 4,2 2,6 20,1 7,9 7,4 4,1 3,7 6,8 3,9 6,8 2,4 7,4 2,2 2,0 2,0 Post marketing experience Adverse drug reactions from spontaneous reports during the worldwide post marketing experience with SPORANOX are included in Table 2. Page 14 of 19
15 Table 2. Post marketing reports of adverse drug reactions. System organ class: Blood and lymphatic system disorders Leucopenia, neutropenia, thrombocytopenia. Immune system disorders Serum sickness, angio oedema, anaphylactic, anaphylactoid and allergic reactions. Metabolism and nutrition disorders Hypertriglyceridaemia, hypokalaemia. Nervous system disorders Peripheral neuropathy, paraesthesia, hypoaesthesia, headache, dizziness. Eye disorders Visual disturbances, including blurred vision and diplopia. Ear and labyrinth disorders Tinnitus, transient or permanent hearing loss. Cardiac disorders Congestive heart failure. Respiratory, thoracic and mediastinal disorders Pulmonary oedema, dyspnoea. Gastrointestinal disorders Pancreatitis, abdominal pain, vomiting, dyspepsia, nausea, diarrhoea, constipation, dysgeusia. Hepato-biliary disorders Serious hepatotoxicity (including cases of fatal acute liver failure), hepatitis, reversible Page 15 of 19
16 increases in hepatic enzymes. Skin and subcutaneous tissue disorders Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, urticaria, alopecia, rash, pruritus, photosensitivity. Musculoskeletal and connective tissue disorders Myalgia, arthralgia. Renal and urinary disorders Pollakiuria, urinary incontinence. Reproductive system and breast disorders Menstrual disorders, erectile dysfunction. General disorders and administrative site conditions Oedema, pyrexia. Less frequent cases of adrenal suppression have been reported, when high doses (600 mg/day) were given. Special Precautions Cardiac effects - SPORANOX Oral solution has been shown to have a negative inotropic effect and SPORANOX has been associated with reports of congestive heart failure. Heart failure was more frequently reported among spontaneous reports of 400 mg total daily dose than among those of lower total daily doses, suggesting that the risk of heart failure might increase with the total daily dose of SPORANOX Oral solution (see Contra- Indications). Page 16 of 19
17 SPORANOX Oral solution should not be used in patients with congestive heart failure or with a history of congestive heart failure unless the benefit clearly outweighs the risk. This individual benefit/risk assessment should take into consideration factors such as the severity of the indication, the dosing regimen (e.g. total daily dose), and individual risk factors for congestive heart failure. These risk factors include cardiac disease, such as ischemic and valvular disease; significant pulmonary disease, such as chronic obstructive pulmonary disease; and renal failure and other edematous disorders. Such patients should be informed of the signs and symptoms of congestive heart failure, should be treated with caution, and should be monitored for signs and symptoms of congestive heart failure during treatment; if such signs or symptoms do occur during treatment, SPORANOX Oral solution should be discontinued. - Calcium channel blockers can have negative inotropic effects which may be additive to those of SPORANOX Oral solution. In addition SPORANOX Oral solution can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when coadministering SPORANOX Oral solution and calcium channel blockers, due to an increase of CHF (See INTERACTIONS). Cystic fibrosis: In cystic fibrosis patients, variability in therapeutic levels of SPORANOX Oral solution was observed with steady state dosing of oral solution using 2,5 mg/kg twice daily. Adequate steady state concentrations of > 250 ng/ml were achieved in approximately 50 % of subjects greater than 16 years of age, but in none of the patients less than 16 years of age. Efficacy and safety of SPORANOX Oral solution in cystic fibrosis patients and children has not been demonstrated. Page 17 of 19
18 KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT In the event of an overdose, supportive measures should be employed. Within the first hour after ingestion, gastric lavage may be performed. Activated charcoal may be given if considered appropriate. No specific antidote is available. Itraconazole cannot be removed by haemodialysis. IDENTIFICATION A yellow to slightly amber, clear solution with a cherry odour. PRESENTATION 150 ml amber glass bottles with a 10 ml measuring cup. STORAGE CONDITIONS Store at or below 25 o C. KEEP OUT OF REACH OF CHILDREN. Use the solution within 3 months after first opening. REGISTRATION NUMBER 30/20.2.2/0429. NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION Page 18 of 19
19 JANSSEN PHARMACEUTICA (PTY) LTD (Reg. No. 1980/011122/07) Building 6, Country Club Estate, 21 Woodlands Drive, Woodmead, Nam. Reg. No. 04/20.2.2/0265 NS 2 DATE OF PUBLICATION OF THIS PACKAGE INSERT 20 th June 2011 Page 19 of 19
Core Safety Profile. Pharmaceutical form(s)/strength: Oral solution 10 mg /ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Oral solution 10 mg /ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY PROFILE Based on EU SmPC sections
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY
More informationItraconazole DIGICON. Composition: MOLECULAR INTRODUCTION
Itraconazole DIGICON Composition: Itraconazole 100 mg MOLECULAR INTRODUCTION Itraconazole is a triazole medicine used to treat fungal infections. It is effective against a broad spectrum of fungi including:
More informationSPORANOX Capsules Janssen
SPORANOX Capsules Janssen NAME OF THE MEDICINAL PRODUCT SPORANOX CAPSULES QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 100 mg itraconazole in a pellet formulation. PHARMACEUTICAL FORM
More informationITRANOX. Composition Each capsule contains :
ITRANOX Composition Each capsule contains : Itraconazole 100 mg Capsules Action Itraconazole is a synthetic triazole derivative. When administered orally, it has shown fungistatic activity against superficial
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Itrakonazol Actavis 100 mg, hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule, hard contains 100 mg of itraconazole.
More informationRead all of this leaflet carefully before you start taking your medicine:
PACKAGE LEAFLET: INFORMATION FOR THE USER Sporanox 10mg/ml Oral Solution (itraconazole) Read all of this leaflet carefully before you start taking your medicine: Keep this leaflet. You may need to read
More informationPRODUCT INFORMATION. DAKTARIN Oral Gel
PRODUCT INFORMATION DAKTARIN Oral Gel NAME OF THE MEDICINE Miconazole DESCRIPTION [Miconazole, 1-(2(2,4-dichlorophenyl)-2-(2,4-dichlorophenyl)methoxy]ethyl)-1H-imidazole, is a synthetic 1-phenethyl-imidazole
More informationREGIONAL ADMINISTRATIVE INFORMATION. 3. Pharmaceutical form Capsule, hard Elongated, red opaque hard gelatine capsule (size 0)
MODULE 1: Module 1.3.1 REGIONAL ADMINISTRATIVE INFORMATION Summary of Product Characteristics 1. Name of the medicinal product 2. Qualitative and quantitative composition Each capsule contains 100 mg of
More informationREGIONAL ADMINISTRATIVE INFORMATION
MODULE 1: Module 1.3.1 REGIONAL ADMINISTRATIVE INFORMATION Summary of Product Characteristics 1. Name of the medicinal product 2. Qualitative and quantitative composition Each capsule contains 100 mg of
More informationJanssen NAME OF THE MEDICINAL PRODUCT
NIZORAL Tablets Janssen NAME OF THE MEDICINAL PRODUCT NIZORAL Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200 mg ketoconazole. For excipients, see List of Excipients PHARMACEUTICAL
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationSAJA PHARMA. Itraconazole 1. NAME OF THE MEDICINAL PRODUCT
08-15 ITRAZOL 100 mg Capsules SAJA PHARMA Itraconazole 1. NAME OF THE MEDICINAL PRODUCT ITRAZOL 100 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ITRAZOL in pink and blue capsules coded by SJ153,
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Sporanox 100 mg capsules. Itraconazole
PACKAGE LEAFLET: INFORMATION FOR THE USER Sporanox 100 mg capsules Itraconazole Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again
More informationNizoral 200 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Nizoral 200 mg tablets Ketoconazole Nizoral is a registered trademark Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration
More informationSPORANOX Capsules Itraconazole Consumer Medicine Information
SPORANOX Capsules Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX capsules. It does not contain all the available information.
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationEach 1 ml of solution contains 50 micrograms palonosetron (as hydrochloride).
Approved PI: 13 Jun 2014 Page 1 of 12 SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM ONICIT (solution for injection) COMPOSITION Each 1 ml of solution contains 50 micrograms palonosetron (as hydrochloride).
More informationThe sensitivity of fungal microorganisms to fluconazole is as follows:
FLUCAN Composition Each capsule contains Fluconazole 50, 100 or 150 mg Capsules Action Fluconazole is a triazole anti-fungal, which in sensitive fungi, inhibits cytochrome P450-dependent enzymes resulting
More informationPfizer Laboratories (Pty) Ltd. Page 1 of 33 Vfend 50 mg & 200 mg Tablets and 200 mg IV Approved Package Insert 12 October 2015 APPROVED PACKAGE INSERT
Pfizer Laboratories (Pty) Ltd. Page 1 of 33 SCHEDULING STATUS S4 APPROVED PACKAGE INSERT PROPRIETARY NAMES AND DOSAGE FORMS VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets VFEND IV 200
More informationAPO-ITRACONAZOLE Itraconazole capsules
APO- Itraconazole capsules Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 WHAT IS IN THIS LEAFLET This leaflet answers some common questions about APO-. It does not
More informationTILAZEM. Diltiazem hydrochloride 240 mg
Tilazem Capsules Page 1 of 9 TILAZEM Diltiazem hydrochloride SCHEDULING STATUS: S3 PROPRIETARY NAME (AND DOSAGE FORM): TILAZEM 180 CR (controlled-release capsule) TILAZEM 240 CR (controlled-release capsule)
More informationPACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent
PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationFLUCAND HIKMA PHARMACEUTICALS
09-15 FLUCAND HIKMA PHARMACEUTICALS (Fluconazole) Description Flucand is a crystalline white - whitish powder, which is slightly soluble in water and in a saline solution. Its molecular weight is 306.3.
More informationKELFER Capsules (Deferiprone)
Published on: 22 Sep 2014 KELFER Capsules (Deferiprone) Composition KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg Dosage Form
More informationData Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.
BICALOX Data Sheet Bicalutamide 50 mg tablets Presentation BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. Uses Actions
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Trimethoprim 100 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 100 mg of trimethoprim. For the full list
More informationPRODUCT INFORMATION ITRANOX capsules
PRODUCT INFORMATION ITRANOX capsules NAME OF THE MEDICINE Itraconazole CAS-84625-61-6 C 35 H 38 CI 2 N 8 O 4 MW: 705.64 (+)-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-
More informationSCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets
SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less S1 For pack sizes of more than 24 tablets PROPRIETARY NAME: AND DOSAGE FORM PANADO MELTABS (Tablets) COMPOSITION: Each tablet contains 500 mg
More informationPRODUCT INFORMATION APO-Itraconazole capsules
PRODUCT INFORMATION APO-Itraconazole capsules NAME OF THE MEDICINE Itraconazole CAS-84625-61-6 C35H38CI2N8O4 MW: 705.64 (+)-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationPROFESSIONAL INFORMATION
SCHEDULING STATUS: S1 PROPRIETARY NAME AND DOSAGE FORM: Aleve Tablets COMPOSITION: Each tablet contains naproxen sodium 220 mg (equivalent to 200 mg naproxen) CATEGORY AND CLASS: A / 2.7 Antipyretic or
More informationPharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:
0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013
More informationRecommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml
Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:
Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity
More informationBefore you take ITRACAP. When you must not take it
ITRACAP Itraconazole CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about ITRACAP Itraconazole capsules. It does not contain all the available information.
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Itrafungol 10 mg/ml Oral Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION mg/ml Active substance(s): Itraconazole 10 Excipients:
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationEach tablet contains:
Composition: Each tablet contains: Tolvaptan 15/30mg Pharmacokinetic properties: In healthy subjects the pharmacokinetics of tolvaptan after single doses of up to 480 mg and multiple doses up to 300 mg
More informationPACKAGE INSERT FOR MYCOBUTIN
SCHEDULING STATUS: S4 PACKAGE INSERT FOR MYCOBUTIN PROPRIETARY NAME (AND DOSAGE FORM): MYCOBUTIN (Capsules) COMPOSITION: Each capsule contains 150 mg rifabutin. The other ingredients are microcrystalline
More informationAcilight 75mg Tablets. Ranitidine Hydrochloride 83.57mg eq.to Ranitidine 75mg. Generic Name: Ranitidine Hydrochloride 83.57mg eq.
Acilight 75mg Tablets Company name: El- Obour Modern Pharmaceutical Industries co. Trade Name: Acilight 75mg Film Coated Tablets Generic Name: Ranitidine Hydrochloride 83.57mg eq.to Ranitidine 75mg Pharmaceutical
More informationAnnex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications
Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1. Patients with known hypersensitivity to cephalosporin
More informationNevirapine 200mg Tablet WHOPAR part 4 May 2005 Section 7 updated: May 2016 SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Nevirapine 200mg Tablet. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nevirapine 200 mg. For excipients, see section
More information* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte.
Trade Name Aciloc 75 mg & 300 mg Film-coated tablets Generic Name Ranitidine Composition Each Aciloc 300 mg film-coated tablet contains: - Active ingredient: Ranitidine hydrochloride 336 mg equivalent
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT TRANSISOFT 8.5 g powder for oral solution in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 8.5 g of macrogol
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR:
M0BCore Safety Profile Active substance: Pantoprazole Pharmaceutical form(s)/strength: several forms and strength P-RMS: DE/H/PSUR/0039/001 Date of FAR: 05.12.2013 Annex I : CSP 4.3 Contraindications Hypersensitivity
More information(itraconazole) Oral Solution BOXED WARNING
SPORANOX (itraconazole) Oral Solution BOXED WARNING Congestive Heart Failure, Cardiac Effects and Drug Interactions: If signs or symptoms of congestive heart failure occur during administration of SPORANOX
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationFarmadol. Paracetamol 10 mg/ml INFUSION SOLUTION
Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties
More informationCABAZITAXEL Prostate Cancer
Systemic Anti-Cancer Treatment Protocol CABAZITAXEL Prostate Cancer PROCTOCOL REF: MPHACABAZ (Version No: 1.0) Approved for use in: Cabazitaxel in combination with prednisolone is a treatment option for
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 5.631g fosfomycin trometamol equivalent to 3.0 g fosfomycin.
Doctor leaflet 1. NAME OF THE MEDICINAL PRODUCT MONUROL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 5.631g fosfomycin trometamol equivalent to 3.0 g fosfomycin. Excipients: One sachet
More informationSupply of Clarithromycin by Community Pharmacists to Patients with an Exacerbation of COPD Protocol No: 300 Version 2
Supply of Clarithromycin by Community Pharmacists to Patients with an Exacerbation of COPD Protocol No: 300 Version 2 Date protocol prepared: April 2010 Date protocol due for review: April 2012 This patient
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections
More informationMOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)
MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) NAME OF THE MEDICINE: MOVICOL Liquid Orange Flavour, Concentrate for Oral Solution. DESCRIPTION: A clear colourless solution.
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationItraconazole Capsules
Itraconazole Capsules Rx only BOXED WARNING Congestive Heart Failure, Cardiac Effects and Drug Interactions: Itraconazole capsules should not be administered for the treatment of onychomycosis in patients
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationZYDELIG PBS. (idelalisib) RETHINK WHAT S POSSIBLE... LISTED 1
RETHINK WHAT S POSSIBLE... ZYDELIG (idelalisib) PBS LISTED 1 st 1 September 2017 ZYDELIG a first-in-class oral PI3Kδ inhibitor is PBS listed from 1 st September 2017 for the treatment of: Double-refractory
More informationPackage leaflet: Information for the patient. Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin
Package leaflet: Information for the patient Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPRODUCT MONOGRAPH. Fluconazole Tablets, House Standard 50 mg and 100 mg ANTIFUNGAL AGENT
PRODUCT MONOGRAPH Pr pms-fluconazole Fluconazole Tablets, House Standard 50 mg and 100 mg ANTIFUNGAL AGENT PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 Date of Revision:
More informationFluconazole is a white to off-white crystalline powder which is sparingly soluble in water and saline.
Fluzole PRODUCT INFORMATION Name of the medicine Fluconazole is a bis-triazole: 2-(2,4-difluorophenyl)-1,3-bis (1H-1,2,4-triazol-1-yl)-2-propanol. C 13H 12F 2N 6O Molecular weight: 306.3 CAS No.: 86386-73-4
More informationSPORANOX Oral Solution Itraconazole
SPORANOX Oral Solution Itraconazole Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SPORANOX Oral Solution. It does not contain all the available
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More information4.4 Special warnings and precautions for use
SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative
More informationITRALASE Capsules (Itraconazole)
Published on: 20 Dec 2017 ITRALASE Capsules (Itraconazole) Black Box Warning Congestive Heart Failure, Cardiac Effects and Drug Interactions Itraconazole capsules should not be administered for the treatment
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Terbinafine Dermapharm, 10 mg/g, cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of cream contains 10 mg of terbinafine hydrochloride.
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flavamed Hustensaft 15 mg/5 ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of oral solution contains 3 mg ambroxol
More information1. NAME OF THE MEDICINAL PRODUCT. Lamisil 1% cutaneous solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Lamisil 1% cutaneous solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: 10 mg terbinafine hydrochloride per 1 g solution (1% w/w). Excipient(s) with
More informationPRODUCT INFORMATION. ASPEN FLUCONAZOLE Injection for Intravenous Infusion
PRODUCT INFORMATION ASPEN FLUCONAZOLE Injection for Intravenous Infusion NAME OF THE MEDICINE Non proprietary name: Fluconazole injection for intravenous infusion Chemical name: 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-propan-2-ol
More informationFor the use of a Registered Medical Practitioner or a Hospital or a Laboratory only
For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only Fluconazole Injection USP 2mg/ml FORCAN /FORCAN PLUS COMPOSITION FORCAN I.V. Each 100mL contains: Fluconazole IP... 200
More informationShaded areas=not MARKETED 24/2/09
PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME AND DOSAGE FORM RAPIFEN 2 ml IV injection RAPIFEN 10 ml IV injection COMPOSITION Each ml contains alfentanil hydrochloride 0,544 mg (equivalent
More informationRanitidine hydrochloride syrup containing 150mg Ranitidine per 10mL
Peptisoothe Ranitidine hydrochloride syrup containing 150mg Ranitidine per 10mL Presentation PEPTISOOTHE is a clear to pale yellow syrup with a spearmint flavour. Each 10mL of the syrup contains ranitidine
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory GRISOVIN- FP. Griseofulvin Tablets I.P.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory GRISOVIN- FP Griseofulvin Tablets I.P. 250 mg / 500 mg QUALITATIVE AND QUANTITATIVE COMPOSITION Each uncoated tablet contains:
More informationMOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350)
MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Chocolate Flavour Product Description: Each sachet of MOVICOL Junior Chocolate contains: Macrogol 3350
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known
More informationThe long plasma elimination half-life provides the basis for single dose therapy for vaginal candidiasis.
Data Sheet OZOLE fluconazole 150 mg capsule Presentation OZOLE 150 mg is available for oral administration as a size 1 hard gelatin capsule with an opaque blue body and cap containing 150 mg fluconazole.
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: soft capsules/20, 30, 40, 80 mg CZ/H/PSUR/0009/002 Date of FAR:
M0BCore Safety Profile Active substance: Vinorelbine Pharmaceutical form(s)/strength: soft capsules/20, 30, 40, 80 mg P-RMS: CZ/H/PSUR/0009/002 Date of FAR: 01.07.2013 4.2 Posology and method of administration
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationVESIGARD Tablets (Darifenacin hydrobromide)
Published on: 10 Jul 2014 VESIGARD Tablets (Darifenacin hydrobromide) Composition VESIGARD 7.5 Extended Release Tablets Each tablet contains: Darifenacin (as a hydrobromide).. 7.5 mg Dosage Form Tablets
More informationEmergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains
More information